Germany-headquartered Bayer (ETR: BAYN) recently published interim insights from a significant real-world observational study focusing on the clinical characteristics and treatment patterns associated with its mineralocorticoid receptor antagonist (MRA), Kerendia (finerenone). This medication has received global approvals aimed at reducing cardiorenal risk in patients suffering from chronic kidney disease (CKD) related to type 2 diabetes (T2D).
The findings from the study highlight crucial data regarding the incidence of hyperkalemia in real-world settings, recorded at 5%. Furthermore, the study categorized participants based on their risk levels: 2% were classified as low risk, 22% as moderate risk, 27.9% as high risk, and a significant 48.2% as very high risk.
Notably, the research also documented the rate of treatment interruption or discontinuation, which stood at 6.4% following a median follow-up period of 7 months. These insights underscore the importance of ongoing monitoring and tailored treatment strategies in managing CKD and T2D effectively.-Fineline Info & Tech
